Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017)

Alaa Badawi1,2*, Giancarlo Di Giuseppe3, Paul Arora3,4

1 Public Health Risk Sciences Division, Public Health Agency of Canada, Toronto, ON, Canada, 2 Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 3 Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4 Division of Enteric Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Toronto, ON, Canada

* alaa.badawi@canada.ca

Abstract

The role of hepatitis C virus (HCV) infection in increasing the risk of cardiovascular disease (CVD) is controversial. The objective of the present study is to estimate the 10-year risk of CVD in HCV-positive subjects and describe their profile of cardiometabolic risk markers compared to HCV-negative subjects. We conducted a cross-sectional study to estimate 10-year CVD risk, calculated using the Framingham Risk Score (FRS), in participants from the Canadian Health Measures Survey (CHMS; 2007–2015, n = 10,115) and the US-National Health and Nutrition Examination Survey (NHANES; 2007–2016, n = 16,668). Subjects included in our analysis were aged 30 to 74 years with no prior history of CVD. FRS estimates, sociodemographic and cardiometabolic risk factors were compared between HCV-positive and -negative subjects in the two surveys. HCV-positive subjects had a distinct sociodemographic profile compared to their HCV-negative counterparts. Cardiometabolic risk factors, inflammatory markers and serum levels of micronutrients were comparable between the two survey populations, both in HCV-positive and -negative subjects. The average FRS in HCV-positive patients was in the range of “intermediate” 10-year CVD risk (i.e., 10–20%) and was significantly higher (P<0.01) than their HCV-negative counterparts who were within the “low” 10-year CVD risk range (i.e., ≤10%). Using a multivariable linear regression model adjusted for ethnicity, number of metabolic syndrome components and BMI, HCV infection was significantly associated with a 2.5–3.5% absolute risk increase of 10-year CVD (P<0.01). The results of the present study suggest a potential association between HCV infection and risk of subclinical and clinical CVD. The expansion of anti-HCV therapy may also contribute to reduced CVD risk and burden in patients with chronic HCV infection and should be explored further in other datasets and population modelling studies.
information. This DUA is signed between the Public Health Agency of Canada (PHAC) and the Data Providers (Statistics Canada and the Canadian Institute of Health Information) and is disseminated by the Data Coordination and Access Program (DCAP). This DUA obligates the data user to protect the confidentiality of the information, not to disclose it or distribute it improperly, and to comply with all relevant laws, federal government policies and practices. Any information received under this DUA is to be treated as “Protected Data”. This includes, among others, personal information (i.e., as defined by the Privacy Act), Furthermore, according to the DUA, the Data User is required to comply with the Agency’s specific contractual obligations, in particular those related to access and confidentiality. Also, the DUA states that “Protected Data” may not be shared with individuals or organizations within or outside the signed Agency. Individual permissions to access the CHMS data may, however, be requested from Statistics Canada (https://www.statcan.gc.ca) or the Canadian Institute of Health Information (https://www.cihi.ca) through DCAP (contact information, email: dcap-pacd@phac-aspc.gc.ca).

Funding: This work was supported by Public Health Agency of Canada. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

HCV infection is endemic worldwide, with an estimated global prevalence of 2.5–3%, causing chronic liver diseases in 170–200 million people [1–3]. Presently, HCV is the leading cause of progressive liver fibrosis, resulting in cirrhosis, liver cancer, liver failure and death [2–4]. The rate of mortality amongst persons living with HCV currently surpasses that of those living with human immunodeficiency virus (HIV) infections [5–6]. HCV exerts its main effects in the liver leading to hepatic fibrosis and subsequent cirrhosis in about 20% of the chronically infected cases [7]. HCV infection may also exert an effect extrahepatically [8, 9] leading to abnormal endocrine, hematologic, neurologic and renal functions [10, 11]. In addition to liver diseases, over the past decade, several longitudinal studies have shown that patients with chronic HCV infection also experience increased rates of cause-specific mortality from cardiovascular disease (CVD) [12–16].

The association of HCV infection with CVD is still an issue of controversy. Some reports have demonstrated a higher CVD risk among HCV-infected persons [17, 18] whereas others have not reported such an association [19, 20]. The role of HCV in the development of CVD was thought to be related to interference of the infection with glucose and lipid metabolism [21] that may result in the development of metabolic syndrome and subsequent risk of developing insulin resistance (IR), type 2 diabetes and CVD. Beyond this metabolic dysregulation, HCV infection was also thought to increase CVD risk via mechanisms that facilitate chronic inflammation and/or endothelial dysfunction [21].

With CVD presently being the leading cause of death worldwide [22], an improved understanding of disease risk may help tailor interventions and prevention efforts in patients infected with HCV. A number of prediction scores such as the Framingham Risk Score (FRS) [23], European Systematic Coronary Risk Evaluation (SCORE) function [24], the PROCAM (Prospective Cardiovascular Münster) model [25], the QRISK function [26] and the Reynolds functions [27, 28] have been developed to estimate 10-year risk of cardiovascular outcomes. These prediction models are used to identify high-risk patients who would benefit from interventions on one or more risk factors. The FRS is the most commonly used risk prediction score in North America [23] both for clinical and research purposes [23, 29]. It was developed in the USA [23] and validated in Canada [29] as a means to predict CVD risk in asymptomatic patients. This gender-specific multivariate function (algorithm) estimates risk of CVD including coronary heart diseases, cerebrovascular events, peripheral artery disease and heart failure [23, 30].

There are several distinct FRS models which can be used for either diabetic or non-diabetic patients. In general, FRS combines the information in CVD risk factors such as sex, age (usually, 30–74 years), systolic blood pressure, total cholesterol (T-Chol), high-density lipoprotein cholesterol (HDL-C), smoking behavior, the status of diabetes and use of antihypertensive medications to produce the 10-years estimate (or risk) of developing CVD. CVD events estimated from the FRS are defined as coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and health failure [23]. These estimates of CVD risk can subsequently be used to guide pharmacological or behaviour-based preventive measures.

The objective of the present study is to determine the association between 10-year risk of CVD and HCV infection status in otherwise healthy subjects from nationally representative surveys, namely the Canadian Health Measures Survey (CHMS) and the National Health and Nutrition Examination Survey (NHANES) from Canada and USA, respectively. This measure will provide additional information to encourage further debate on the potential role of HCV
in CVD risk, and ultimately contribute to the body of evidence needed to explore the development of more targeted CVD preventive actions for those living with HCV.

Methods
Study population and eligibility criteria
Data were collected from the Canadian Health Measures Survey (CHMS) and the US National Health and Nutrition Examination Survey (NHANES). Both CHMS and NHANES are cross-sectional surveys of the noninstitutionalized civilian Canadian and US resident populations, respectively, designed to collect information on the health and wellness as well as nutrition status of both populations.

The CHMS survey is conducted by Statistics Canada to collect information from Canadians aged 3 to 79 years, from households in the ten provinces and three territories of Canada. Those living on Aboriginal Reserves or Crown Lands, in institutions and certain remote regions, and full-time members of the Canadian Forces were not captured by this survey. The CHMS covers approximately 96.3% of the Canadian population at the selected age group. CHMS data included in this study were obtained from cycles 1 to 4 collected between March 2007 and December 2015 (Cycle 1: March 2007 to February 2009, \( n = 5,604 \); Cycle 2: August 2009 to November 2011, \( n = 6,395 \); Cycle 3: January 2012 to December 2013, \( n = 5,785 \) and Cycle 4: January 2014 to December 2015, \( n = 5,794 \)). Comprehensive details of the CHMS multistage sampling design and data collection methods have been previously published [31–33]. Briefly, a multi-stage sampling strategy was used to identify the sites from which data was collected. Participants (\( n = 23,578 \)) signed a consent form prior to participating in the study. Participation was voluntary and included a household interview that included general sociodemographic questions as well as an in-depth health questionnaire. Subsequently, participants visited a mobile examination centre (MEC) where physical and biological measurements were taken. The study was reviewed and approved by the Health Canada Research Ethics Board [34].

The NHANES survey is conducted by the National Center for Health Statistics (NCHS), CDC. The survey examines a nationally representative sample of approximately 5,000 individuals of all age groups each year from all counties across the USA. All of the study methods were approved by the NCHS research ethics review board. All of the participants provided informed consent. NHANES participants are selected by using a complex multistage sampling design [35]. Similar to the CHMS, the NHANES includes an in-home health interview and a physical examination in a MEC in addition to a follow-up telephone interview. This analysis includes data from five cycles of NHANES 2007/08, 2009/10, 2011/12, 2013/14, and 2015/16 (\( n = 50,526 \)). Detailed methods of the NHANES survey construction and sampling strategy have been previously described [36, 37]. Each NHANES survey cycle is a stratified, multistage, probability random sample designed to represent the noninstitutionalized house-dwelling US civilian population.

The FRS algorithm was developed in a study population aged 30 to 74 without a history of CVD event at baseline. Therefore, we excluded subjects under the age of 30 years or over the age of 74 years (CHMS: \( n = 12,348 \); NHANES: \( n = 29,483 \)) as they were not relevant to the FRS algorithm. FRS guidelines restricts the use this tool for people between 30 and 74 years old [23]. History of CVD was assessed via self-report. Survey participants were asked by health professionals if they have or had heart disease and they were asked if they have ever been told by health professional that they have or had heart attack. An answer of “yes” to any of these questions resulted in exclusion from the current study. Patients with confirmed (or with a history of) heart diseases (CHMS: \( n = 888 \); NHANES: \( n = 1,852 \)) were excluded. Participants with
missing data for any of the components used in the algorithm of the FRS (i.e. age, gender, blood pressure, T-Chol, HDL-C, smoking status, diabetes, anti-hypertensive medication) were also excluded as the FRS could not be calculated (CHMS: n = 51; NHANES: n = 705). Moreover, participants missing information on HCV status or with an indeterminate HCV infection (CHMS: n = 176; NHANES: n = 1,880) were not included. Ultimately, the total number of participants included in the present study was 10,115 subjects from the CHMS survey (male:female ratio of 1:1.12) and 16,668 subjects (male:female ratio of 1:1.09) from the NHANES survey (see Fig 1). This group was further divided to HCV+ (CHMS: n = 87; NHANES: n = 326) and HCV- (CHMS: n = 10028; NHANES: n = 16,342) subgroups.

**Hepatitis C infection and cardiovascular disease risk**

In both surveys, infection with HCV was classified using laboratory-confirmed samples. Infection status was determined using serum specimens screened for anti-HCV antibodies or HCV RNA. A participant was considered “HCV-positive” if a confirmed antibody test yielded positive results or viral HCV RNA was present in the serum. Participants with an indeterminate antibody test and negative RNA test were considered “HCV-negative”, whereas those with indeterminate anti-HCV and without RNA testing were considered “unknown” and were excluded as HCV status could not be determined with certainty. HCV infection was detected...
using VITROS Anti-HCV Assay (Ortho-Clinical Diagnostics, Raritan, NJ, USA) in both surveys. All samples positive on initial screening for anti-HCV were confirmed by INNO-LIA HCV Score immunoblot assay (Innogenetics, Fugirebio Inc., GA, US) in the CHMS, and by Chiron RIBA 3.0 Strip Immunoblot Assay (SIA; Chiron Corporation, Inc.) in the NHANES. Indeterminate and positive HCV samples in NHANES were further tested for viral RNA in the serum samples using the COBAS AMPLICOR HCV Test, version 2.0 (Roche Diagnostics Corp., Indianapolis, IN). In the NHANES HCV-positive individuals ($n = 326$), a total of 239 had anti-HCV test results and 304 had HCV-RNA testing done. HCV status was assigned by only one lab test result using anti-HCV and HCV-RNA only in 22 and 87 individuals, respectively. A total of 217 had both anti-HCV and HCV-RNA testing done with 167/217 had both a positive anti-HCV and HCV-RNA test, and 48/217 had a positive anti-HCV test but negative HCV-RNA test, while the remaining 2 having indeterminate anti-HCV test but positive HCV-RNA results (S1 Table). All 87 CHMS HCV-positive patients had anti-HCV testing performed. Among those, 21 subjects were also examined for HCV-RNA, 14 of which were positive for HCV-RNA. In participants from both surveys, information on the use of the recent direct-acting antivirals were not available.

**Estimating the 10-year risk of CVD**

Estimates of 10-year CVD risk in asymptomatic subjects was determined using the FRS points-based method [23] in HCV positive (HCV+) and HCV-negative (HCV-) subjects. The FRS algorithm has been described extensively previously [23] and has been validated in the USA [23] and Canada [29], both in White and African American subjects. We calculated the raw FRS score for each participant based on the individual's sex, age, systolic blood pressure, T-Chol, HDL-C, smoking status (smoker or non-smoker), presence or absence of diabetes and the use of antihypertensive medications. The points assigned for each risk factor are based on the value for the $\beta$-coefficient of the proportional hazard regressions [23, 29]. The 10-year risk score is then derived as a percentage. As previously described [29], 10-year CVD risk is considered low if the FRS-derived estimate is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.

**Sociodemographic factors, metabolic markers and other covariates**

Sociodemographic information was captured through responses to questionnaires given during the structured interview portion of each survey and included: age, gender, ethnicity, education, marital status, history of injection drug use, and household income. Ethnicity was categorized into 4 main subgroups: White, African Americans, Asian (i.e., Korean, Filipino, Japanese, Chinese, South Asian, Southeast Asian, Arab, and West Asian), and Other (i.e. Latin American or mixed racial origins). Household income was dichotomized according to self-reported income below or above $20,000 per annum. Self-reported smoking status was categorized into smokers (daily/occasional) and non-smokers.

A number of metabolic markers were measured in both the CHMS and NHANES and were available for the present study. These included cardiometabolic disease markers (apolipoprotein [Apo] A1 [g/L], ApoB [g/L], LDL-C [mmol/L], HDL-C [mmol/L], T-Chol [mmol/L], T-Chol:HDLC ratio, triglycerides [mmol/L], and glycosylated hemoglobin [HbA1c] [%]); inflammatory biomarkers (CRP [mg/L], fibrinogen [g/L], and homocysteine [μmol/L]); systolic and diastolic blood pressure; and plasma 25-hydroxyvitamin D (25(OH)D) (nmol/L) [38]. Factors related to obesity such as body mass index (kg/m$^2$), waist circumference (cm) and waist-to-hip were all assessed as previously described [38]. Diabetes status was defined as a self-reported or HbA1c $\geq$ 6.5% [39]. The US National Cholesterol Education Program Adult
Treatment Panel III (ATPIII) criteria were used to define metabolic syndrome [40, 41]. The presence of at least three of the following five metabolic risk factors constitutes a diagnosis of metabolic syndrome: abdominal obesity (waist circumference ≥102 cm in men and ≥88 cm in women), elevated triglyceride level (1.7 mmol/L), reduced HDL-C level (1.0 mmol/L in males; 1.3 mmol/L in females), elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mmHg), and elevated fasting plasma glucose level (≥5.6 mmol/L) [41]. Individuals who have already been diagnosed as hypertensive, diabetic, or those who were using antihypertensive drugs were included [40–42]. Insulin resistance (IR) was approximated using the homeostatic model assessment (HOMA-IR) formula [(glucose (mmol/L) x insulin (μIU/mL)) ÷ 22.5] [43, 44]. Liver functions were evaluated in both survey studies using serum enzyme markers of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase and γ-glutamyl transferase. Furthermore, a number of serum micronutrients including vitamins B12, C, and D were measured in both the CHMS and NHANES and were captured in the present study.

Statistical analysis
All analyses were stratified by HCV infection status and by RNA positivity within the HCV positive cases and performed separately on Canadian and US participants. Guidelines and principles published by NHANES and CHMS were used to combine survey data over multiple cycles [23, 45, 46]. Data from each cycle were treated as a completely random population sample and survey weights were excluded from all analyses. Frequency distributions and means (±standard deviation) were used to describe baseline characteristics. Associations between HCV group and baseline characteristics were determined using t-test and χ² tests for continuous and categorical variables, respectively. Fisher’s exact test was used for categorical data analysis where there were small sample sizes. Sociodemographic characteristics and levels of biomarkers and cardiometabolic risk factors as well as the FRS values were all compared between HCV-positive and negative cases as well as between RNA-positive and—negative cases in HCV infected subjects. Linear regression was used to explore the association between FRS (outcome = 10-year CVD risk) and HCV infection status. Unadjusted and adjusted regression analyses were conducted with two models hypothesized a priori. A multivariable regression model was used to control for ethnicity, BMI, and the number of Adult Treatment Panel III (ATPIII) components [47]. We used the ATPIII score in the multivariable model since it is a composite measure of factors accounting for overall cardiovascular health. The degree of missing data was assessed for each variable and was considered for multivariable regression model inclusion. If a variable had >80% missing data, it wouldn’t be fit to be included in the regression model. There was no statistically significant difference between the proportion of missing data and HCV status, thus data was considered missing at random. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, North Carolina) at the Public Health Agency of Canada.

Results
A total of 23,578 Canadians responded to the CHMS during the study period, of which 10,115 (43%) were eligible for this study. Similarly, a total of 50,588 individuals in the USA responded to five cycles of NHANES, and 16,668 (33%) met eligibility criteria. The selection procedure of the study population is illustrated in Fig 1. The prevalence of HCV among NHANES participants (1.95%, n = 326) was about 2-fold higher than their CHMS counterparts (0.9%, n = 87).

Baseline sociodemographic characteristics of the study population stratified by HCV status are shown in Table 1 for each survey. Although the Canadian population was predominantly
Whites (80%), there was higher ethnic diversity in the NHANES survey. Except for gender frequency, and use of hypertensive medications in the CHMS study, all sociodemographic characteristics were significantly different between the HCV-infected patients and non-infected subjects. In both surveys, HCV-infected individuals were, on average, older, had higher frequency of being single, lower education level, lower income, and with increased smoking rates compared to their non-infected counterparts (see Table 1). Recreational (intravenous) drug use was significantly (\(P<0.001\)) higher in HCV-infected patients than non-infected subjects both in the USA (33% vs. 1%) and Canada (53% vs. 1%). As shown in Table 2, when HCV positive cases in each survey were stratified by the RNA positivity (i.e., the status of viremia), no significant differences were shown in the Canadian or the US subjects between HCV-RNA-negative and -positive cases. Exceptions in the NHANES HCV-positive cases included a

| Characteristic | CHMS | CHMS | NHANES | NHANES | \(p^1\) |
|---------------|------|------|--------|--------|---------|
| Respondents   | 10028 | 100 | 87 | 100 | 16342 | 100 | 326 | 100 | <0.001 |
| Males         | 4722 | 47 | 46 | 53 | 7753 | 47 | 212 | 65 | <0.001 |
| Age (yr), (mean±SD)\(^2\) | 49±13 | 51±10 | 0.033 | 50±12 | 53±9 | <0.001 |
| Ethnicity     |       |     |       |       |       |       |       |       |       |
| White         | 8070 | 80 | 70 | 80 | 3265 | 20 | 104 | 32 | <0.001 |
| African Americans | 245 | 2 | 2 | 2 | 4650 | 28 | 73 | 22 |       |
| Asian         | 1138 | 11 | 3 | 3 | 1274 | 8 | 4 | 1 |       |
| Other         | 575 | 6 | 12 | 14 | 7153 | 44 | 145 | 44 |       |
| Marital Status|       |     |       |       |       |       |       |       |       |
| Married       | 7076 | 71 | 30 | 34 | 10885 | 67 | 161 | 49 | <0.001 |
| Divorced      | 1729 | 17 | 24 | 28 | 3504 | 21 | 114 | 35 |       |
| Single        | 1223 | 12 | 33 | 38 | 1953 | 12 | 51 | 16 |       |
| Highest Level of Education Obtained |       |     |       |       |       |       |       |       |       |
| Less than grade 12 | 1111 | 11 | 20 | 23 | 4046 | 25 | 125 | 38 | <0.001 |
| High-school graduate | 1954 | 19 | 28 | 32 | 8084 | 49 | 180 | 55 |       |
| Post-secondary graduate | 6859 | 68 | 39 | 45 | 4203 | 26 | 20 | 6 |       |
| Household Income |       |     |       |       |       |       |       |       |       |
| < $20,000 per annum | 729 | 7 | 36 | 41 | 2824 | 17 | 125 | 38 | <0.001 |
| History of intravenous drug use |       |     |       |       |       |       |       |       |       |
| 85 | 1 | 46 | 53 | <0.001 | 147 | 1 | 108 | 33 | <0.001 |
| Metabolic syndrome, n (%) |       |     |       |       |       |       |       |       |       |
| 10028 | 87 | 16342 | 326 |       |       |       |       |       |
| <3 | 8644 | 86 | 76 | 87 | 10611 | 65 | 218 | 67 |       |
| ≥3 | 1384 | 14 | 11 | 13 | 5731 | 35 | 108 | 33 |       |
| Medication Use for Hypertension |       |     |       |       |       |       |       |       |       |
| 1677 | 17 | 16 | 18 | 4187 | 25 | 104 | 30 | 0.016 |
| Diabetes, n (%)\(^4\) |       |     |       |       |       |       |       |       |       |
| 789 | 8 | 11 | 13 | 2313 | 14 | 46 | 14 |       |
| Smoking Status |       |     |       |       |       |       |       |       |       |
| Daily / Occasional | 1832 | 18 | 57 | 66 | <0.001 | 3767 | 23 | 199 | 61 | <0.001 |
| Non-smoker | 8196 | 82 | 30 | 34 | 12575 | 77 | 127 | 39 |       |

\(^1\)Only respondents aged 30–74 years were considered for the purpose of this study.

\(^2\)Unweighted frequency.

\(^3\)\(\chi^2\) test for the difference between hepatitis C virus-positive (HCV+) and -negative (HCV-) cases. Only significant differences are shown.

\(^4\)Diabetes defined as Hb1Ac ≥ 6.5% or self-reported diabetic as per survey questionnaire.

https://doi.org/10.1371/journal.pone.0208839.t001
significant age increase and higher rates of using antihypertensive medications in the HCV-RNA-positive cases.

Mean levels of cardiometabolic biomarkers, factors related to obesity, inflammatory markers, micronutrients and liver enzyme markers are presented in Table 3 and stratified by the HCV infection status. The mean levels of these factors were all within normal clinical ranges.

Table 2. Sociodemographic characteristics of the hepatitis C virus (HCV) infected subjects stratified by the HCV-RNA status.

| Characteristic                          | CHMS (n = 87) | NHANES (n = 326) |
|----------------------------------------|---------------|-------------------|
|                                        | HCV-RNA-     | HCV-RNA+          | HCV-RNA-     | HCV-RNA+          |
|                                        | n  | %  | n  | %  | P  | n  | (%) | n  | (%) | P  |
| Respondents (underwent RNA analysis)   |    |    |    |    |    |    |    |    |    |    |
| Yes (n)                                | 7  | 14 | 48 | 256|    |    |    |    |    |    |
| No (n)                                 | 66 | 22 |    |    |    |    |    |    |    |    |
| Males                                  | 3  | 43 | 9  | 64 | 35 | 73 | 165| 64 |    | 0.021|
| Age (yr), (mean±SD)                    | 52±13 | 53±9 | 50±9 | 53±9 | 0.039 |
| Ethnicity                              |    |    |    |    |    |    |    |    |    |    |
| White                                  | 6  | 86 | 10 | 72 | 7  | 15 | 92 | 36 |    |    |
| African Americans                      | 1  | 7  |    |    | 12 | 25 | 55 | 22 |    |    |
| Asian                                  | 1  | 14 |    |    | 3  | 1  |    |    |    |    |
| Other                                  | 3  | 21 |    |    | 29 | 60 | 106| 41 |    |    |
| Marital Status                         |    |    |    |    |    |    |    |    |    |    |
| Married                                | 3  | 43 | 4  | 29 | 26 | 54 | 123| 48 |    |    |
| Divorced                               | 2  | 29 | 4  | 29 | 13 | 27 | 94 | 37 |    |    |
| Single                                 | 2  | 29 | 6  | 42 | 9  | 19 | 39 | 15 |    |    |
| Highest Level of Education Obtained    |    |    |    |    |    |    |    |    |    |    |
| Less than grade 12                     | 5  | 36 | 14 | 29 | 103| 40 |    |    |    |    |
| High-school graduate                   | 3  | 43 | 4  | 28 | 28 | 58 | 138| 54 |    |    |
| Post-secondary graduate                | 4  | 57 | 5  | 36 | 6  | 13 | 14 | 15 |    |    |
| Household Income                       |    |    |    |    |    |    |    |    |    |    |
| < $20,000 per annum                    | 2  | 29 | 7  | 50 | 15 | 33 | 103| 40 |    |    |
| History of intravenous drug use        | 2  | 29 | 7  | 50 | 20 | 43 | 81 | 32 |    |    |
| Metabolic syndrome, n (%)              | 7  | 14 |    |    | 48 |    | 256|    |    |    |
| <3                                     | 5  | 71 | 13 | 93 | 32 | 67 | 172| 67 |    |    |
| ≥3                                     | 2  | 29 | 1  | 7  | 16 | 33 | 84 | 33 |    |    |
| Medication Use for Hypertension        | 1  | 14 | 2  | 14 | 8  | 17 | 83 | 32 | 0.029|
| Diabetes, n (%)                        | 1  | 14 | 3  | 21 | 3  | 6  | 39 | 15 |    |    |
| Smoking Status                         |    |    |    |    |    |    |    |    |    |    |
| Daily / Occasional                     | 3  | 43 | 10 | 71 | 24 | 50 | 163| 64 |    |    |
| Non-smoker                             | 4  | 57 | 4  | 29 | 24 | 50 | 93 | 36 |    |    |

1 Only respondents aged 30–74 years were considered for the purpose of this study.
2 Unweighted frequency within the corresponding HCV-RNA status.
3 $\chi^2$ test for the difference between hepatitis C virus-RNA-positive (HCV-RNA+) and -negative (HCV-RNA-) cases. Only significant differences are shown.
4 Diabetes defined as Hb1Ac $\geq$ 6.5% or self-reported diabetic as per survey questionnaire. Empty cells denote no subjects are available in the corresponding characteristic.

https://doi.org/10.1371/journal.pone.0208839.t002
| Biomarker                  | CHMS (n = 10028) | HCV+ (n = 87) | P<sup>1</sup> | NHANES (n = 16342) | HCV+ (n = 326) | P<sup>1</sup> |
|---------------------------|------------------|--------------|--------------|-------------------|----------------|--------------|
| **Cardiometabolic risk markers** |                  |              |              |                   |                |              |
| Systolic blood pressure (mmHg) | 10028           | 114±15       | 87           | 115±21            | 16342          | 123±17       | <0.001 |
| Diastolic blood pressure (mmHg) | 10028           | 73±9         | 87           | 75±10             | 16342          | 72±12        | 0.031 |
| Triglycerides, fasting (mmol/L) | 5066            | 1.43±0.89    | 41           | 1.15±0.52         | 6412           | 1.52±1.4    | 0.015 |
| Total cholesterol (mmol/L) | 10028           | 3.94±1.27    | 87           | 4.50±0.97         | <0.001         | 16342        | 5.17±1.1    | <0.001 |
| LDL-C (mmol/L) | 5023            | 3.03±0.92    | 41           | 2.48±0.89         | <0.001         | 6269         | 3.09±0.9    | 0.013 |
| HDL-C (mmol/L) | 10028           | 1.38±0.40    | 87           | 1.42±0.45         | 16342          | 1.37±0.4    | 0.013 |
| Total cholesterol:HDL-C ratio | 10028           | 3.94±1.27    | 87           | 3.37±1.01         | <0.001         | 16342        | 4.10±1.5    | 0.013 |
| Insulin, fasting (pmol/L) | 5016            | 77±67        | 41           | 94±62             | 4715           | 83±95        | 104          | 0.1021 |
| Glucose, fasting (mmol/L) | 2418            | 5.30±1.26    | 23           | 5.63±2.23         | 6402           | 6.05±2.0    | 132          | 0.6282 |
| HOMA-IR | 2417            | 3.5±3.9      | 23           | 4.4±3.5           | 4706           | 4.0±5.6     | 104          | 0.5411 |
| HbA1c (%) | 9774            | 5.61±0.77    | 85           | 5.67±0.88         | 16313          | 5.81±1.1    | 326          | 0.5711 |
| Apolipoprotein A1, fasting (g/L) | 3661           | 1.46±0.27    | 32           | 1.49±0.28         | –              | –            | –            | –     |
| Apolipoprotein B, fasting (g/L) | 3660           | 0.97±0.26    | 32           | 0.75±0.20         | <0.001         | 6412         | 0.95±0.2    | 0.013 |
| **Obesity** |                  |              |              |                   |                |              |
| Body mass index (kg/m²) | 10004           | 27.9±5.7     | 85           | 26.9±5.7          | 16219          | 29.5±6.8    | 321          | 0.001 |
| Waist circumference (cm) | 9927            | 94.6±15.3    | 87           | 94.5±15.7         | 15884          | 100.1±15.7  | 313          | 0.001 |
| Waist-to-hip ratio | 9918            | 0.90±0.1     | 86           | 0.93±0.1          | 0.004          | –            | –            | –     |
| **Inflammatory markers** |                  |              |              |                   |                |              |
| C-reactive protein (mg/L) | 9754            | 2.5±2.9      | 84           | 2.5±3.2           | 6750           | 4.2±7.8     | 171          | 0.026 |
| Fibrinogen (mmol/L) | 5190            | 3.1±0.6      | 39           | 2.9±0.6           | 0.042          | –            | –            | –     |
| Homocysteine (umol/L) | 2524            | 8.2±3.0      | 18           | 9.0±3.3           | –              | –            | –            | –     |
| **Micronutrients** |                  |              |              |                   |                |              |
| Vitamin B12 (pmol/L) | 9804            | 340±193      | 85           | 362±145           | 6396           | 462±343     | 115          | 0.4623 |
| Vitamin D (nmol/L) | 9985            | 64±26        | 87           | 64±27             | 9404           | 63±26       | 147          | 0.6331 |
| Vitamin C (nmol/L) | 1226            | 52±23        | 4            | 33±43             | –              | –            | –            | –     |
| **Liver enzyme markers** |                  |              |              |                   |                |              |
| Alanine aminotransferase (U/L) | 7243           | 33±16        | 61           | 63±54             | <0.001         | 16284        | 26±19       | 0.001 |
| Alkaline phosphatase (U/L) | 9985            | 78±24        | 86           | 90±36             | 0.004          | 16288        | 69±24       | 0.001 |
| Aspartate aminotransferase (U/L) | 9984           | 28±12        | 86           | 55±47             | <0.001         | 16282        | 26±18       | 0.001 |
| γ-Glutamyl transferase (U/L) | 10000          | 32±37        | 86           | 92±176            | 0.002          | 16289        | 30±43       | 0.001 |
| Lactate dehydrogenase (U/L) | 2291           | 381±86       | 17           | 427±67            | 0.028          | 16281        | 129±31      | 0.001 |

<sup>1</sup>t-test for the difference between hepatitis C virus positive (HCV+) and negative (HCV-) case. Only significant differences are shown.  
<sup>2</sup>Variable are not captured by survey.

Regardless of HCV infection status. However, serum levels of triglycerides, LDL-C, T-Chol, HDL-C, and ApoB were all significantly lower in HCV-positive participants than in non-infected subjects. The HCV-positive participants from the CHMS had higher total cholesterol than non-infected Canadians (4.50±0.97 vs. 3.94±1.27 mmol/L; P<0.001). In contrast, HCV-positive participants from the NHANES had lower total cholesterol than the non-infected Americans (4.67±1.0 vs. 5.17±1.1 mmol/L; P<0.001). HCV status was associated with a lower body mass index in both survey populations. There was no association between the diabetic status (self-reported or using the Hb1Ac cut-off ≥6.5%) and HCV-infection status. Similarly,
the frequency of metabolic syndrome did not differ between HCV-infected and non-infected subjects both in the CHMS and the NHANES surveys. Levels of inflammatory markers and concentrations of micronutrients were similar in both infected and control subjects with the exception of CRP (in NHANES) and fibrinogen (in CHMS) that were slightly—but significantly—lowered in the HCV-infected patients. As expected, all serum markers for liver functioning enzymes were significantly elevated in HCV-positive subjects. As shown in Table 4, when HCV positive cases in each survey were stratified by the RNA positivity, although from a

Table 4. Levels of biomarkers and cardiometabolic risk factors in the hepatitis C virus (HCV) infected subjects stratified by the HCV-

| Biomarker                                      | CHMS (n = 87)                                                                 | NHANES (n = 326)                                                                 |   |
|------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|---|
|                                                | HCV-RNA- (n = 7)                                                             | HCV-RNA+ (n = 14)                                                             |   |
| n mean±SD                                      | n mean±SD                                                                    | n mean±SD                                                                     |   |
| Cardiometabolic risk markers                   |                                                                               |                                                                               |   |
| Systolic blood pressure (mmHg)                 | 7 119±16                                                                     | 14 130±36                                                                     |   |
| Diastolic blood pressure (mmHg)                | 7 78±10                                                                      | 14 79±11                                                                      |   |
| Triglycerides, fasting (mmol/L)                | 4 1.16±0.67                                                                  | 16 1.31±0.48                                                                  |   |
| Total cholesterol (mmol/L)                    | 7 4.5±1.2                                                                    | 14 4.2±0.64                                                                   |   |
| LDL-C (mmol/L)                                 | 4 1.68±0.47                                                                  | 16 3.51±1.05                                                                  |   |
| HDL-C (mmol/L)                                 | 7 1.24±0.45                                                                  | 14 1.70±0.68                                                                  |   |
| Total cholesterol:HDLC ratio                  | 7 3.89±1.02                                                                  | 14 2.74±0.74                                                                 |   |
| Insulin, fasting (pmol/L)                      | 4 88±37                                                                      | 16 97±86                                                                      |   |
| Glucose, fasting (mmol/L)                      | 4 7.95±5.02                                                                  | 16 6.10±1.87                                                                  |   |
| HOMA-IR                                        | 4 6.1±6.0                                                                    | 16 4.3±3.8                                                                    |   |
| HbA1C (%)                                      | 7 5.56±1.07                                                                  | 13 5.97±1.58                                                                 |   |
| Apolipoprotein A1, fasting (g/L)               | 4 1.67±0.41                                                                  |                                                                               |   |
| Apolipoprotein B, fasting (g/L)                | 4 0.73±0.20                                                                  | 16 1.06±0.27                                                                  |   |
| Obesity                                        |                                                                               |                                                                               |   |
| Body mass index (kg/m²)                        | 7 27.01±5.42                                                                 | 14 23.75±4.05                                                                 |   |
| Waist circumference (cm)                       | 7 98.2±13.1                                                                  | 14 89.1±14.1                                                                 |   |
| Waist-to-hip ratio                             | 7 0.95±0.08                                                                  | 14 0.93±0.1                                                                  |   |
| Inflammatory markers                           |                                                                               |                                                                               |   |
| C-reactive protein (mg/L)                      | 6 4.27±4.01                                                                  | 13 0.93±0.92                                                                  |   |
| Fibrinogen (mmol/L)                            |                                                                               |                                                                               |   |
| Homocysteine (umol/L)                          |                                                                               |                                                                               |   |
| Micronutrients                                  |                                                                               |                                                                               |   |
| Vitamin B12 (pmol/L)                           | 7 371±229                                                                    | 14 355±169                                                                    |   |
| Vitamin D (nmol/L)                             | 7 53±25                                                                      | 14 68±39                                                                      |   |
| Vitamin C (nmol/L)                             | 4 33±43                                                                      |                                                                               |   |
| Liver enzyme markers                           |                                                                               |                                                                               |   |
| Alanine aminotransferase (U/L)                 |                                                                               |                                                                               |   |
| Alkaline phosphatase (U/L)                     |                                                                               |                                                                               |   |
| Aspartate aminotransferase (U/L)               |                                                                               |                                                                               |   |
| γ-Glutamyl transferase (U/L)                   |                                                                               |                                                                               |   |
| Lactate dehydrogenase (U/L)                    |                                                                               |                                                                               |   |
| FRS (%)                                        | 7 11.0±12.5                                                                  | 14 13.5±8.3                                                                   |   |

RNA status.

1t-test for the difference between hepatitis C virus-RNA-positive (HCV-RNA+) and -negative (HCV-RNA-) cases. Only significant differences are shown.

Empty cells denote either variables that were not captured by survey (see Table 3) or no subjects are available in the corresponding biomarker.

https://doi.org/10.1371/journal.pone.0208839.t004
small sample size, there was a tendency—between the two surveys HCV-RNA-positive cases—
to have higher levels of systolic blood pressure and lower total cholesterol, LDL-C, total cholesterol:
HDL-C ratio and ApoB than the RNA-negative HCV infected cases. As expected during
the active HCV infection, liver enzymes were significantly increased in the HCV-RNA-positive
cases compared to the -negative ones. Furthermore, FRS value, only in the NHANES HCV-
positive cases, was significantly ($P$ = 0.047) higher in the RNA-positive cases (15.3 ±
10.4%) than in the -negative (12.1 ± 9.8%) cases.

As shown in Table 5, the average 10-year risk of CVD estimated by the FRS (%) was higher
in the HCV-infected group when compared to uninfected participants from the USA (14.7
±10.3 vs. 10.0±10.0; $P<0.001$) and Canada (10.5±8.8 vs. 8.0±6.6; $P = 0.008$). Furthermore, the
CVD risk was found to be higher among NHANES participants on a population level when
compared to Canadians in both HCV-infected ($P<0.0001$) and uninfected ($P = 0.0006$) sub-
jects. There was no difference between HCV-RNA status in the mean FRS score between
HCV-RNA positive (14.14 ± 10.03%) and RNA-negative (12.06 ± 9.76) individuals who were
positive for anti-HCV antibodies ($P = 0.20$) from the NHANES population. Furthermore, in
the CHMS study, there was no significant difference in the mean FRS score between the
RNA-HCV-positive (13.46±8.65) and -negative subjects (11.03±12.54) among those 21 indi-
viduals who had both antibody and RNA testing ($P = 0.60$). In an unadjusted linear regression
model, HCV infection was associated with a 4.21% ($P<0.001$) and 2.47% ($P = 0.008$) higher
10-year CVD risk estimated by the FRS in the American and Canadian participants, respec-
tively. After controlling for ethnicity, number of metabolic syndrome components, and body
mass index, HCV infection remained associated with a higher CVD risk. The difference
between HCV-positive and HCV-negative subjects in 10-year absolute risk of CVD was higher
in American subjects (3.5%, $P<0.001$) compared to their Canadian counterparts (2.5%,
$P<0.003$).

**Discussion**

Results of the present study suggest that HCV infection is associated with an increased 10-year
risk of CVD and bolsters the findings of previous meta-analyses [6, 48] evaluating CVD risk
and mortality in HCV-positive patients. Based on data from national surveys, sampled from
the general population of Canada and the United States, our results suggest that 10-year CVD
risk was 2.5–3.5% higher in HCV-infected subjects compared to the HCV-negative population.
In the present study, the 10-year risk of CVD was estimated to be approximately 8% and

---

| Population | Predicted 10-Year CVD risk (%) | $P$ | $\beta$ Estimates of linear regression (%) | Model 1 | $\beta$ Estimates of linear regression (%) | Model 2 |
|------------|---------------------------------|---|------------------------------------------|---------|------------------------------------------|---------|
|            | $P^1$                           |   |                                          | $P^2$   |                                          | $P^3$   |
| CHMS       | 87                              | 10.5±8.8 | 10028 | 8.0±6.6 | 0.008 | 2.47 | 0.65–4.30 | 0.008 | 2.49 | 0.83–4.16 | 0.003 |
| NHANES     | 326                             | 14.7±10.3 | 16342 | 10±10.0 | $<$0.001 | 4.21 | 3.12–5.30 | $<$0.001 | 3.48 | 2.48–4.48 | $<$0.001 |

$P^1$ Significance for the difference in CVD risk (estimated from by the FRS) between HCV infected and non-infected subjects (t-test).

$P^2$ Significance for the difference in CVD risk (estimated from by the FRS) between participants from CHMS and NHANES within each HCV-infection subgroup (t-test).

$P^3$ Linear regression models are for risk of CVD (estimated from by the FRS) in hepatitis C virus infected cases vs. non-infected controls.

$P^4$ Unadjusted model.

$P^5$ Multivariate model adjusted for ethnicity, number of metabolic syndrome components, and body mass index.

We did not control for CVD risk factors that were already included in the FRS algorithm.

https://doi.org/10.1371/journal.pone.0208839.t005
10% in the general Canadian and American populations, respectively (Table 5). Similar estimates were previously observed in both populations from the national representative surveys evaluated in our study. Using the same methods to calculate the FRS, Setayeshgar et al., reported the 10-year CVD risk in Canadian adults (from the CHMS study) to be 8.1% [42]. In the American general population, however, Lopez-Jimenez et al., assessed 10-year CVD risk from the NHANES survey to be 11% [49]. These estimates are similar to what we observed in the HCV-negative subjects.

In the HCV-infected subjects, the CVD risk estimates generated from the NHANES survey was 14.7% (Table 5). This risk level was comparable to the 10-year CVD risk of ~12% previously assessed in the same study population [50]. To our knowledge, the present study is the first to estimate the 10-year risk of CVD in HCV infected subjects and the association between the two conditions in the Canadian population using population-based survey data. Our results suggest an approximately 11% elevated CVD risk due to HCV infection in the Canadian population. In the Ontario HIV Treatment Network Cohort Study, the rates of CVD events in a large cohort of HIV mono-infected and HIV/HCV co-infected patients was previously evaluated [51]. In that study, the authors reported a 1.2-fold higher incidence of CVD events and a 1.4-fold elevated risk of CVD in the co-infected patients compared to those mono-infected with HIV [51].

We noted differences in the prevalence of HCV in relation to the marital status, age, schooling, income, the smoking status and the frequency of the intravenous drug use (Table 1). Similar sociodemographic characteristics were observed in different HCV infected populations around the world [52–55]. These findings may facilitate a better understand of the HCV transmission modes in North America and enable effective approaches for intervention. Furthermore, in our study population, a distinctive pattern of various cardiometabolic risk factors was observed in the HCV-infected patients (Table 2). Increasing severity of liver diseases has long been associated with progressively lower lipid levels and a range of metabolic disorders. For example, the induction of hepatic steatosis was found to be a risk factor leading to insulin sensitivity, metabolic abnormalities and visceral obesity [56]. Our results (Table 2) confirm previous reports demonstrating lower levels of LDL-C [57, 58], TGs [59] and ApoB [60] at the various stages of chronic HCV infection. This disrupted pattern of serum lipid profile can be the result of deteriorating liver functions [61] indicating that virus itself may be involved in the imbalance of serum lipoproteins/apolipoproteins [60] which is a known risk factor in atherosclerosis and CVD [62]. In support, several lines of recent evidence indicate that HCV by itself or factors associated with the infection can promote the occurrence and progression of atherosclerosis [63, 64]. For example, a recent meta-analysis indicates that HCV infection is significantly associated with carotid atherosclerosis, independent of classical risk factors such as type 2 diabetes, insulin resistance or hepatic steatosis [63]. HCV-positive participants from NHANES had lower cholesterol than their noninfected counterparts from the same survey, and further that HCV status is associated with lower BMI in both surveys. These findings can be explained by the recent reports showing that patients with HCV genotype 3 have lower total cholesterol than other infected patients with different genotypes [65]. Additional evidence for the role of viremia in CVD risk and its effect on cardiometabolic risk factors can be substantiated from our results (between the two surveys) demonstrating that in HCV cases who were also positive for the viral DNA there is lower total cholesterol, LDL-C and total cholesterol: HDL-C ratio than the RNA-negative HCV infected cases. Further, lower BMI can be linked to the status of persons who inject drugs of these patients. Moreover, elevation of proinflammatory cytokines in chronic HCV may be involved in the progression of atherosclerosis [9]. Although the levels of proinflammatory cytokines were not assessed in the two evaluated surveys, the downstream acute phase reactants (APR) such as CRP (NHANES and CHMS),
fibrinogen (CHMS) and homocysteine (CHMS) were examined. In the present study, both CRP and fibrinogen levels were lower in the HCV-infected subjects compared to their non-infected counterparts (Table 2). In agreement, several studies have shown that CRP levels are downregulated in HCV patients [66–68] and plasma fibrinogen concentration progressively decreases as liver cirrhosis worsened [69] in patients with hepatic-nephrotic disease [70]. Taken together, it is possible that HCV infection (and/or replication) may blunt CRP synthesis [68] and lead to a state of acquired fibrinogen deficiency [69]. These interrelationships may however not explain the profiles of CRP and fibrinogen in the present study populations—as fibrosis parameters and platelet count (a good measure of chronic liver disease stage)—were not measured. A close relationship may be suggested between the severity of cirrhosis and alteration in the hemostatic regulation of the fibrinolytic system that is closely linked to control of inflammation and a role in CVD risk [9]. Indeed, activation of inflammatory processes, disruption of cytokine synthesis and imbalance in APR homeostasis are well-known risk factors in the increased CVD risk [48, 71, 72]. Overall, it was proposed that liver cirrhosis in HCV infection may accelerate atherosclerosis [48, 73, 74] leading to higher prevalence of carotid plaques [75] and increased risk of cardiovascular morbidity and mortality [76, 77]. Several factors were also proposed to mediate the link between HCV infection and risk of CVD [48, 78]. These include: augmented oxidative stress, modified iron homeostasis [48, 79], activation of immunological and/or inflammatory processes leading to a disrupted cytokine imbalance [48, 80] and induction of hepatic steatosis, a risk factor in insulin sensitivity and related metabolic abnormalities [56].

This study has several limitations which should be considered. For example, the limited data on intravenous drug use did not permit including this factor into our model. As expected, this behavior was highly associated with HCV infection as previously noted in the Canadian users [81]. Furthermore, HIV status was not captured into our study. The NHANES survey uses laboratory testing on 20- to 59-year-old participants whereas this was not available for the CHMS except for the self-reported information. This discrepancy rendered comparison between the two survey studies not feasible given the potential for bias of self-reported data inherent in conducting analyses on population-based surveys. HIV status has been linked to CVD risk in subjects co-infected with HCV [50]. Another limitation of the present study is that we were unable to examine the effect of ethnicity on the CVD risk in HCV patients. Ethnicity did not influence the CVD risk in the in the Canadian HCV positive patients (P = 0.41, ANOVA test). However, in the NHANES cohort, HCV-positive White subjects had a significantly higher (P<0.001) FRS score (18.0 ± 10.5) than that in the other ethnic groups (African Americans: 14.2 ± 10.6; Asians: 17.4 ± 11.9; others 12.4 ± 9.3). In both populations nevertheless, a suggestion of any ethnic-related CVD risk difference in HCV patients cannot be substantiated as it is severely underpowered by the small number of participants from the different ethnic groups. Moreover, our inability to combine the two population samples due to the different approaches taken in estimating various risk factors may have hindered acquiring a large sample size—particularly from the Canadian survey—to improve the outcome of our study. However, the definition of HCV status used was based on laboratory-confirmation after initial HCV screening was carried out using antibody tests. This protocol is known to result in significant reduction of false-positives and an accurate exposure definition [42, 49]. In this regard, there was no significant difference in CVD risk between HCV-RNA positive and negative status in those who had a positive anti-HCV result in participants from both the NHANES (P = 0.85) and CHMS (P = 0.21) surveys. This is critical as the direct-acting antiviral therapies offer sustained virologic response rates of almost 100%, the CVD risk may be decreased after successful antiviral therapy, a response that can be compared between cases with anti-HCV positive and HCV-RNA negative tests and those with anti-HCV positive and HCV-RNA...
positive test results. It was not surprising to find no difference in the FRS score between the two segregated groups mentioned above (i.e., anti-HCV positive/HCV-RNA positive cases vs. anti-HCV positive/HCV-RNA negative cases) given the small sample size of the RNA positive cases within the studied populations and also in light of the well-known large interindividual variation within the FRS factors that is usually present in humans. Overall, our results are in line with previous estimates of CVD risk from the same two populations [42, 49, 50]. Using data from two general population surveys produced two nearly similar estimates which represent the HCV-infected and -uninfected subpopulations of the US and Canada. In conclusion, using data from two general population surveys from Canada and the USA, we report 11–15% elevated 10-year risk of CVD in HCV-infected individuals with no history of this chronic condition at baseline. When the relationship between HCV infection and CVD is adjusted for confounders there was 2.5–3.5% absolute increased risk of cardiovascular events due to HCV infection. Using cross-sectional surveys in the present study resulted in similar estimates of the 10-year risk of CVD when compared to prospective studies, e.g., in the Canadian population [51]. Patients with HCV may, therefore, benefit from a frequent monitoring of surrogate markers of CVD risk such as the range of cardiometabolic factors and inflammatory markers. This may assist in establishing more specific CVD prevention strategies. Although studies from the US [82] and Canada [83] indicate a shift in HCV seroprevalence and decreased infection rates in younger generations, the burden of the disease on the healthcare cost remains significant. For example, in Canada, it has been estimated that chronic HCV costs are projected to rise by 60% by 2035 [84]. The recent availability of large-scale HCV therapy using direct-acting antivirals that is both highly effective and well-tolerated may aid in reducing the projected healthcare cost associated with HCV infection. Furthermore, apparently viremia is an important factor in the risk prediction of future CVD. This can be demonstrated from the significantly lower 10-year disease risk in HCV-positive cases (from the NHANES population) who were also positive for the viral RNA. Indeed, similar results were not attainable from the Canadian cases (due to the small size) and this outcome was generated from a limited number of US cases. However, this increased 10-year CVD risk in viremia may substantiate its critical role in the development of the chronic disease and—more importantly—that antiviral therapy should be highly encouraged as it can directly improve the cardiovascular risk in addition to its effect on the infection outcome. Understanding the relationship between HCV and CVD, and how this relationship is affected by population-level HCV reductions, has public health implications for CVD control, a leading cause of morbidity worldwide.

Supporting information
S1 Table. Number of hepatitis C virus (HCV) infected patients stratified by the method of HCV detection.
(PDF)

Acknowledgments
This work was supported by the Public Health Agency of Canada (AB). We thank the US Centers for Disease Control and Prevention (CDC) for permitting the use of the US-National Health and Nutrition Examination Survey (NHANES) data and Statistics Canada and the Canadian Institute for Health Information (CIHI) for granting a the permission to access the Canadian Health Measures Survey data.
Author Contributions
Conceptualization: Alaa Badawi.
Data curation: Alaa Badawi, Giancarlo Di Giuseppe, Paul Arora.
Formal analysis: Giancarlo Di Giuseppe.
Funding acquisition: Alaa Badawi.
Investigation: Paul Arora.
Methodology: Alaa Badawi.
Supervision: Alaa Badawi.
Writing – original draft: Alaa Badawi.
Writing – review & editing: Alaa Badawi, Giancarlo Di Giuseppe, Paul Arora.

References
1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000; 20: 1–16.
2. Petruzzello A, Marigliano S, Loquerco G, Cozzollino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22: 7824–7840. https://doi.org/10.3748/wjg.v22.i34.7824 PMID: 27678366
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3: 47–52. PMID: 16614742
4. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004; 44: 20–29.
5. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: European Centre for Disease Prevention and Control; 2010. Available at https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf. Accessed July 4, 2018.
6. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxi A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 2016; 150: 145–155. https://doi.org/10.1053/j.gastro.2015.09.007 PMID: 26386298
7. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014; 46 (Suppl 5): S165–S173.
8. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008; 49: 831–844. https://doi.org/10.1016/j.jhep.2008.06.006 PMID: 18814931
9. Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of cardiovascular disease due to chronic hepatitis C infection: A review. J Clin Transl Hepatol. 2017; 5: 343–362. https://doi.org/10.14218/JCTH.2017.00021 PMID: 29226101
10. Khattab MA, Eslam M, Alavian SM. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat. Mon. 2010; 10: 258–269.
11. Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J. Clin. Gastroenterol. 2004; 38: 901–905. PMID: 15492610
12. Kristiansen MG, Lechen ML, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. J Viral Hepat. 2011; 18: 237–244. https://doi.org/10.1111/j.1365-2893.2010.01290.x PMID: 20337923
13. Guilltman AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008; 167: 743–750. https://doi.org/10.1093/aje/kwm370 PMID: 18203734
14. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894–2900. https://doi.org/10.1161/STROKEAHA.110.598136 PMID: 20966408
15. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012; 206:469–477. https://doi.org/10.1093/infdis/jis385 PMID: 22811301

16. Vajdic CM, Pour SM, Olivier J, Swart A, O’Connell DL, Falster MO, et al. The impact of bloodborne viruses on cause-specific mortality among opioid dependent people: an Australian population-based cohort study. Drug Alcohol Depend. 2015; 152: 264–271. https://doi.org/10.1016/j.drugalcdep.2015.03.026 PMID: 25936861

17. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009; 49:225–232. https://doi.org/10.1086/599371 PMID: 19508169

18. Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging 2012; 32: 421–430. https://doi.org/10.1111/j.1475-097X.2012.01152.x PMID: 23031062

19. Pothineni NV, Rochlani Y, Vallurupalli S, Kovelamudi S, Ahmed Z, Hakeem A, et al. Comparison of angiographic burden of coronary artery disease in patients with versus without hepatitis C infection. Am J Cardiol. 2015; 116: 1041–1044. https://doi.org/10.1016/j.amjcard.2015.06.035 PMID: 26256578

20. Wong RJ, Kanwal F, Younossi ZM, Ahmed A. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci. 2014; 59: 1586–1593. https://doi.org/10.1007/s10620-014-3222-3 PMID: 24894512

21. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014; 61: S69–S78. https://doi.org/10.1016/j.jhep.2014.08.003 PMID: 25443347

22. World Health Organization. The top 10 causes of death.2018. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed July 4, 2018.

23. D’Agostino R.B.; Vasan R.S.; Pencina M.J.; Wolf P.A.; Cobain M.; Massaro J.M.; et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579 PMID: 18212285

24. Conroy RM, Pyorälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987–1003. PMID: 12788299

25. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 2002; 105:310–315. PMID: 11804985

26. Hippius-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007; 335: 136. https://doi.org/10.1136/bmj.39261.471806.55 PMID: 17615182

27. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297: 611–619. https://doi.org/10.1001/jama.297.6.611 PMID: 17299196

28. Ridker PM, Paytnner NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118: 2243–2251. https://doi.org/10.1161/CIRCULATIONAHA.108.814251 PMID: 18997194

29. Bosomworth NJ. Practical use of the Framingham risk score in primary prevention Canadian perspective. Can Fam Physician. 2011; 57: 417–423. PMID: 21626897

30. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847. PMID: 9603539

31. Tremblay MS, Gorbey SC, Canadian Health Measures Survey: Brief overview. Can J Pub Health. 2007; 98: 453–456.

32. Tremblay M, Wolfson M, Connor Gorbey S. Canadian Health Measures Survey: rationale, background and overview. Heal Rep. 2007; 18: 7–20.

33. Giroux S. Canadian Health Measures Survey: sampling strategy overview. Heal Rep. 2007; 18: 31–36.

34. Day B, Langlois R, Tremblay M, Knoppers BM. Canadian Health Measures Survey: Ethical, legal and social issues. Heal Rep. 2007; 18: 37–51.

35. Mohadjer LMJ, Waksberg J. National Health and Nutrition Examination Survey III: weighting and examination methodology. Hyattsville (MD): Westat, Inc.; 1996.

36. Curtin LR, Mohadjer LK, Dohrmann SM. National Health and Nutrition Examination Survey: Sample Design, 2007–2010. Vital Heal Stat. 2010; 160: 1–32.

37. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National Health and Nutrition Examination Survey: Sample Design, 2011–2014. Vital Heal Stat. 2014; 2: 1–33.
38. Da Costa LA, Arora P, García-Bailo B, Karmali M, El-Soehmy A, Badawi A. The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults. Diabetes Metab Syndr Obes. 2012; 5: 347–355. https://doi.org/10.2147/DMSO.S35115 PMID: 23055759

39. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33(Suppl 1): S62–S69.

40. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005; 112: 2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404 PMID: 16157765

41. Brenner DR, Arora P, García-Bailo B, Wolever TMS, Morrison H, El-Soehmy A, Karmali M, Badawi A. Plasma vitamin D and risk of the metabolic syndrome in Canadians. Clin. Invest. Med. 2011; 34: E377–E384. PMID: 22129928

42. Setayeshgar S, Whiting SJ, Vatanparast H. Prevalence of 10-year risk of cardiovascular diseases and associated risks in Canadian adults: The contribution of cardiometabolic risk assessment introduction. Int J Hyper. 2013; http://dx.doi.org/10.1155/2013/276564

43. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419. PMID: 3899825

44. Badawi A, Sayegh S, Sadoun E, Al-Thani M, Arora P, Haddad PS. Relationship between insulin resistance and plasma vitamin D in adults. Diabet. Metab. Synd. Obes. 2014; 7:297–303.

45. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, et al. National health and nutrition examination survey. Analytic guidelines, 1999–2010. Vital Health Stat 2. 2013; 161: 1–24.

46. Canada Statistics. Instructions for combining multiple cycles of Canadian Health Measures Survey (CHMS) data; 2017. available at https://www.statcan.gc.ca. Accessed on August 23, 2017.

47. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) "final report.". Circulation. 2002; 106: 3143–3421. PMID: 12485966

48. Ambrosino P, Lupoli R, DiMinno R, Tarantino L, Spadarella G, Tarantino P, et al. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. Int J Cardiolo. 2016; 221: 746–754.

49. Lopez-Jimenez F, Batsis JA, Roger VL, Brekke L, Ting HH, Somers VK. Trends in 10-year predicted risk of cardiovascular disease in the United States, 1976–2004. Circ Cardiovasc Qual Outcomes. 2009; 2: 443–450. https://doi.org/10.1161/CIRCOUTCOMES.108.847202 PMID: 20031875

50. Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population Int J Clin Pract. 2013; 67: 6–13. https://doi.org/10.1111/j.1742-1241.2012.02993.x PMID: 23241046

51. Gillis J, Smieja M, Cescon A, Rouke SB, Burchell AN, Cooper C, et al. Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther. 2014; 19: 309–317. https://doi.org/10.3851/IMP2724 PMID: 24429380

52. Mboto CI, Andy IE, Eni Ol, Jewell AP. Prevalence, sociodemographic characteristics and risk factors for hepatitis C infection among pregnant women in Calabar municipality, Nigeria. Hepat Mon. 2010; 10: 116–120. PMID: 22312384

53. Strong C, Hur K, Kim F, Pan J, Tran S, Juon H-S. Sociodemographic characteristics, knowledge and prevalence of viral hepatitis infection among Vietnamese Americans at community screenings. J Immigr Minor Health. 2015; 17: 298–301. https://doi.org/10.1007/s10903-014-0015-x PMID: 24715472

54. Al-Kubaisy WA, Niazi AD. Socio-demographic characteristics as risk factors for hepatitis C virus infection among pregnant women in Iraq. J Women Heal Issues Care 2013; 2: 10. http://dx.doi.org/10.4172/2325-9795.1000106

55. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, et al. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg. 2001; 64: 147–153. PMID: 11442209

56. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utilli R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity, Hepatology 2001; 33: 1358–1364. https://doi.org/10.1053/heap.2001.24432 PMID: 11391523
57. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25:735–739. https://doi.org/10.1002/hep.510250340 PMID: 9049227

58. Hofer H, Banki HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol. 2002; 97:2880–2885. https://doi.org/10.1111/j.1572-0241.2002.07056.x PMID: 12425563

59. Nishimura M, Yamamoto H, Yoshida T, Seimiya M, Sawabe Y, Matsuhashi K, et al. Decreases in the serum VLDL-TG/non-VLDL-TG ratio from early stages of chronic hepatitis C: alterations in TG-rich lipoprotein levels. PLoS One. 2011; 6:e17309. https://doi.org/10.1371/journal.pone.0017309 PMID: 21364889

60. Moriya K, Shintani Y, Fuji H, Miyoshi H, Tsutsumi T, Yotsuyanagi H, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res. 2003; 25:371–376. PMID: 12699847

61. Aizawa Y, Seki N, Nagano T, Abe H. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol. 2015; 21:10299–10313. https://doi.org/10.3748/wjg.v21.i36.10299 PMID: 26420957

62. Malagnuera M, Vacante M, Russo C, Malagnuera G, Antic T, Malagnuera L, et al. Lipoprotein(a) in Cardiovascular Diseases. Biomed Res Int. 2013; 2013: https://doi.org/10.1155/2013/650989

63. Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS One. 2014; 9:e106376. https://doi.org/10.1371/journal.pone.0017309 PMID: 21364889

64. Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis—a systematic review. Clin Physiol Funct Imaging. 2016; 36:249–260. https://doi.org/10.1111/cpf.12229 PMID: 25620553

65. Younossi ZM, Stepanova M, Estep M, Negro F, Clark PJ, Hunt S, et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol. 2016; 64:29–36. https://doi.org/10.1016/j.jhep.2015.08.027 PMID: 26341824

66. Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS. 2007; 21:479–491. https://doi.org/10.1089/apc.2006.0150 PMID: 17651029

67. Shima M, Nakao K, Kato Y, Nakata K, Ishii N, Nagataki S. Comparative study of C-reactive protein in chronic hepatitis B and chronic hepatitis C. Tohoku J Exp Med. 1996; 178:287–297. PMID: 8727711

68. Shah S, Ma Y, Scherzer R, Huhn G, French AL, Plankey M, et al. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels. AIDS. 2015; 29:1325–1333. https://doi.org/10.1097/QAD.0000000000000654 PMID: 25870985

69. Shao Z, Zhao Y, Feng L, Feng G, Zhang J, Zhang J. Association between plasma fibrinogen levels and mortality in acute-on-chronic hepatitis B liver failure. Dis Markers. 2015; 2015:468596. https://doi.org/10.1155/2015/468596 PMID: 25960593

70. Zhou LH, Liu MJ, Dong LJ. Detection of plasma fibrinogen level and function in patients with carcinoma, hepatic-neprotic disease, diabetes mellitus and its clinical significance. Ch J Thromb Hemost. 2001; 7:163–165.

71. Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017; 14:133–144. https://doi.org/10.1038/nrcardio.2016.185 PMID: 27905474

72. Ahmed MS, Jadhav AB, Hassan A, Meng QH. Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm. 2012; 6:2012:953461. https://doi.org/10.5402/2012/953461

73. Kadayifci A, Tan V, Ursel PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NAS and NAS and cirrhosis due to other aetiologies. J. Hepatol. 2008; 49:595–599. https://doi.org/10.1016/j.jhep.2008.05.024 PMID: 18662837

74. Novo G, Macaione F, Giannitrapani L, Minissale MG, Bonomo V, Indovine F, et al. Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. Aliment Pharmacol Ther. 2018; 48:740–749. https://doi.org/10.1111/apt.14934 PMID: 30095177

75. Berzigotti A, Eric E, Gilabert R, Reverter E, Abraudes JG, Garcia-Pagan JC, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am. J. Gastroenterol. 2013; 108:75–82. https://doi.org/10.1038/agj.2012.362 PMID: 23147518
76. Kalaitzakis E, Rosengren A, Skommevik T, Björnsson E. Coronary artery disease in patients with liver cirrhosis. Dig. Dis. Sci. 2010; 55: 467–475. https://doi.org/10.1007/s10620-009-0738-z PMID: 19242795
77. Abougergi MS, Karagozian R, Grace ND, Saltzman JR, Qamar AA. ST elevation myocardial infarction mortality among patients with liver cirrhosis: a nationwide analysis across a decade. J. Clin. Gastroenterol. 2015; 49: 778–783. https://doi.org/10.1097/MCG.0000000000000251 PMID: 25319740
78. Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J. Hepatol. 2013; 5: 528–540. https://doi.org/10.4254/wjh.v5.i10.528 PMID: 24179612
79. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am. J. Gastroenterol. 2002; 97: 2634–2639. https://doi.org/10.1111/j.1572-0241.2002.06041.x PMID: 12385452
80. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin. Biochem. 2001; 34: 167–171. PMID: 11408013
81. Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS. 2007; 18: 23–27. https://doi.org/10.1258/095646207779949880 PMID: 17326858
82. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014; 60: 691–698. https://doi.org/10.1016/j.jhep.2013.11.014 PMID: 24291324
83. Rotermann M, Langlois K, Andonov A, Trubnikov M. Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Heal Rep. 2013; 24: 3–13.
84. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, et al. Burden of disease and cost of chronic hepatitis C virus infection in Canada. Can J Gastroenterol Hepatol. 2014; 28: 243–250. PMID: 24839620